Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Juli 2026 07:00 ET | Quelle: NovMetaPharma

NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy

SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) -- NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that develops first-in-class drugs with...
14. November 2017 16:05 ET | Quelle: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
24. April 2017 08:00 ET | Quelle: aTyr Pharma Inc.

aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting

- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...